REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary
Home > Formulary : Adult > Recent Decisions > 2017 >

Decisions 28th November 2017

At the meeting on the 28th November the following decisions were agreed:

 

New Drug Requests

 

Approved

Ulipristal (TLS green)

  • Approved for inclusion onto the formulary for hormonal emergency contraception

Ganciclovir eye gel (TLS blue)

  • Approved for inclusion onto the formulary for acute herpetic keratitis

Ceftazidime/avibactam (TLS Red)

  • Approved for inclusion onto the formulary on the advice of microbiology for proven multi-drug resistant gram-negative pathogens most likely carbapenem resistant enterobacteriaceae due to KPC or OXA-48 B.lactamases

 Betnesol-N® (TLS green)

  • Approved for inclusion onto the formulary for treatment of otitis externa

 

Shared Care Protocols/TLS change in Status

Degarelix®

  • New SCP, clarification regarding monitoring required

Dymista

  • Further information required for change TLS amber to green

Lidocaine 5%  transdermal Patch (TLS Red to Amber)

  • Change of TLS from red to amber (No SCP) agreed

Cabergoline and bromocriptine

  • New SCP, approved

Penicillamine

  • Updated SCP and advise sheet approved

Gold

  • Updated SCP and advise sheet approved

 

Other

Iron preparations

  • JFG agreed that trusts can decide locally on which preparation are the most cost effective to use in specific clinical situations.